Literature DB >> 19100784

The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Kuei Y Tseng1, R Andrew Chambers, Barbara K Lipska.   

Abstract

Traditionally, animal models of schizophrenia were predominantly pharmacological constructs focused on phenomena linked to dopamine and glutamate neurotransmitter systems, and were created by direct perturbations of these systems. A number of developmental models were subsequently generated that allowed testing of hypotheses about the origin of the disease, mimicked a wider array of clinical and neurobiological features of schizophrenia, and opened new avenues for developing novel treatment strategies. The most thoroughly characterized (approximately 100 primary research articles) is the neonatal ventral hippocampal lesion (NVHL) model, which is the subject of this review. We highlight its advantages and limitations, and how it may offer clues about the extent to which positive, negative, cognitive, and other aspects of schizophrenia, including addiction vulnerability, represent inter-related pathophysiological mechanisms.

Entities:  

Mesh:

Year:  2008        PMID: 19100784      PMCID: PMC2735579          DOI: 10.1016/j.bbr.2008.11.039

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  153 in total

1.  Hippocampal pathologic findings in schizophrenia. A morphometric study.

Authors:  D V Jeste; J B Lohr
Journal:  Arch Gen Psychiatry       Date:  1989-11

2.  Development of the dopaminergic innervation in the prefrontal cortex of the rat.

Authors:  A Kalsbeek; P Voorn; R M Buijs; C W Pool; H B Uylings
Journal:  J Comp Neurol       Date:  1988-03-01       Impact factor: 3.215

3.  Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia.

Authors:  R L Suddath; G W Christison; E F Torrey; M F Casanova; D R Weinberger
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  [The brains of the Vogt collection].

Authors:  B Bogerts
Journal:  Nervenarzt       Date:  1990-05       Impact factor: 1.214

5.  Is schizophrenia a neurodevelopmental disorder?

Authors:  R M Murray; S W Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-19

6.  Search after neurobiological profile of individual-specific features of Wistar rats.

Authors:  A R Cools; R Brachten; D Heeren; A Willemen; B Ellenbroek
Journal:  Brain Res Bull       Date:  1990-01       Impact factor: 4.077

7.  Cell loss in the hippocampus of schizophrenics.

Authors:  P Falkai; B Bogerts
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

8.  Animal models of schizophrenia.

Authors:  W T McKinney; E C Moran
Journal:  Am J Psychiatry       Date:  1981-04       Impact factor: 18.112

9.  Naloxone blockade of morphine analgesia: a dose-effect study of duration and magnitude.

Authors:  R Markowitz; J Jacobson; G Bain; C Kornetsky
Journal:  J Pharmacol Exp Ther       Date:  1976-11       Impact factor: 4.030

10.  The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat.

Authors:  P Voorn; A Kalsbeek; B Jorritsma-Byham; H J Groenewegen
Journal:  Neuroscience       Date:  1988-06       Impact factor: 3.590

View more
  127 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Eur J Neurosci       Date:  2012-04-20       Impact factor: 3.386

Review 4.  Staging perspectives in neurodevelopmental aspects of neuropsychiatry: agents, phases and ages at expression.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

5.  Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: a hypothesis.

Authors:  Dragos Inta; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2010-11-19       Impact factor: 9.306

Review 6.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

7.  A neural model of hippocampal-striatal interactions in associative learning and transfer generalization in various neurological and psychiatric patients.

Authors:  Ahmed A Moustafa; Szabolcs Keri; Mohammad M Herzallah; Catherine E Myers; Mark A Gluck
Journal:  Brain Cogn       Date:  2010-08-21       Impact factor: 2.310

8.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 10.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.